Drug Profile
Donepezil/mefloquine combination regimen - Theranexus
Alternative Names: THN 201Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Theranexus
- Class Antidementias; Antimalarials; Indans; Nootropics; Piperidines; Quinolines; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for phase-I development in Cognition-disorders(In volunteers) in France (PO, Capsule)
- 20 Dec 2019 Theranexus completes a phase I trial in Cognition disorders (Treatment-experienced) in France (PO) (NCT03698695)
- 09 Oct 2018 Theranexus has patent protection for THN 201 in Europe